Scleritis Market Research Report - Forecast till 2030

Scleritis Market Research Report: Information by Type (Anterior and Posterior), Diagnostic Test & Treatment (Ultrasonography, Prednisolone, Ibuprofen, Methotrexate and Mycophenolate), End User (Hospitals & Clinics, Diagnostic Centres) - Forecast till 2030

ID: MRFR/Pharma/1224-HCR | 90 Pages | Published By Rahul Gotadki on March 2023         

Scleritis Market Speak to Analyst Request a Free Sample

Scleritis Market Scenario


The Scleritis Market is expected to reach USD 4,735.3 Million by 2030 at 6.5% CAGR during the forecast period 2022-2030.


Scleritis is a medical condition that causes painful inflammation of sclera (white part of the eye). In some severe cases, the disease is reported to cause loss of vision, i.e., by affecting episclera and sclera. Thus, its timely diagnosis and treatment are necessary against scleritis. Focal redness or violaceous discoloration, scleral thickening, late scleral, and scleral necrosis are some of the prominent symptoms associated with the disease.


It is established that more than 50% of scleritis cases are associated with autoimmune disease, including rheumatoid arthritis. The prevalence of rheumatoid arthritis is increasing and, thus, the susceptible scleritis patient population. It is suggestive that the prevalence of rheumatoid arthritis was about 0.5–1.0% within regional boundaries of North America and Northern Europe. This scleritis market is indicating a positive market growth during the forecast period, 2022–2030.


Moreover, factors such as the growing aging population and increasing per capita healthcare expenditure boost the market growth. However, lack of awareness in the middle-income countries and the absence of targeted treatment is estimated to restraint the market growth during the forecast period.


Segmentation


scleritis market has been segmented into type, diagnostic test & treatment, end-user, and region.


The scleritis market, based on type, has been segmented into anterior scleritis and posterior scleritis. The anterior scleritis segment is further segmented into diffuse scleritis, nodular scleritis, and necrotizing scleritis.


The scleritis global market, by diagnostic test & treatment, has been divided into diagnostic tests and treatment. The diagnostic test market is further segmented into ultrasonography, complete blood count, biopsy, others.


The treatment segment is sub-divided into medication and surgery. The medication segment is further classified into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further classified into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.


The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.


Key Players


Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA) Inc. are some of the key players operating in the scleritis market.  


Regional Market Summary


Scleritis Global Market Share (%), by Region, 2018Scleritis Market Share


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is projected to lead the scleritis market. This can be attributed due to the presence of well-developed healthcare infrastructure and the increasing prevalence of scleritis within the Americas.


Europe is expected to hold the second-largest share of the scleritis market owing to government support and the presence of developed countries such as the UK, Germany, and France within the region.


The scleritis market in Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia-Pacific. The region is estimated to grow with the highest CAGR. High prevalence of scleritis, growing geriatric population, and increasing penetration of market players boost the regional market. In India, the mean age of scleritis patients is estimated to be about 55. This susceptible age group is expanding, which is growing the treatment-seeking patient pool.


The Middle East & Africa is anticipated to hold the least share of the market owing to the presence of poor economies, stringent government regulations, and low per capita income in Africa. Within the region, the Middle East is projected to lead the market owing to developed healthcare infrastructure and the presence of economies such as Saudi Arabia, Kuwait, and Dubai.


Scleritis Market, by Type




  • Anterior Scleritis

    • Diffuse Scleritis

    • Nodular Scleritis

    • Necrotizing Scleritis



  • Posterior Scleritis


Scleritis Market, by Diagnostic Test & Treatment




  • Diagnostic Test

    • Ultrasonography

    • Complete Blood Count

    • Biopsy

    • Others




  • Treatment


    • Medication


      • Corticosteroid

        • Difluprednate

        • Prednisolone

        • Others




      • Nonsteroidal Anti-Inflammatory Drugs

        • Aspirin

        • Ibuprofen

        • Others




      • Immunosuppressive Drugs

        • Methotrexate

        • Mycophenolate

        • Others





    • Surgery




Scleritis Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Academic & Research Organizations


Scleritis Market, by Region




  • Americas

    • North America

    • US

    • Canada

    • South America






  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe






  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea


    • Rest of Asia-Pacific 






  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience

  • Pharmaceutical companies

  • Medical devices companies

  • Contract research organizations

  • Contract manufacturing organizations

  • Research and development organization

  • Academics and research institutes



Report Scope:

Report Attribute/Metric Details
  Market Size   4,735.3 Million
  CAGR   6.5%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising per capita healthcare expenditure.
  • growing aging population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Sceleritis are of two types- anterior and posterior.

    Sceleristis market is predicted to grow at a 6.5% CAGR during 2022-2030.

    The key end users of the scleritis market include academic and research organizations, diagnostic centres, and hospitals and clinics.

    Rising per capita healthcare expenditure and growing aging population are the key factors driving the sceleritis market growth.

    Key players profiled in the scleritis market include Zydus Pharmaceuticals (USA) Inc., West-Ward Pharmaceuticals, Teva Pharmaceuticals USA, Inc., Shanghai Henlius Biotech, Sandoz Inc., Roxane Laboratories, Inc., Perrigo Company, Novartis Pharmaceuticals, Mylan Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., Fresenius Kabi USA, LLC, Boehringer Ingelheim, Baxter International Inc., Amneal Pharmaceuticals LLC, and Amgen.